Modifying the Immune System Can Help Heal Patients with Heart Failure

	Tweet

Modifying the immune system of a patient with heart failure reduces the patient’s risk of death and the need for hospitalization, according to research published in today’s edition of The Lancet.

“Immune modulation therapy could provide physicians with a new way of treating large numbers of patients with heart failure,” said Dr. Guillermo Torre-Amione, principal investigator of the study and cardiologist at the Methodist DeBakey Heart Center in Houston.

Activation of the immune system in patients with systolic heart failure increases the concentration of molecules that can injure the heart in a way that leads to heart failure. New research shows that modification of this immune response is an appealing potential therapy for many patients with heart failure.

The technique involves intentionally damaging some of the patient’s blood cells to trick the body into producing anti-inflammatory cells that heal the damaged heart.

In patients with no history of heart attack, immune modulation therapy (IMT) showed a 26 percent reduction in the risk for death and rehospitalization. In those with Stage 2 NYHA heart failure, those risks were reduced by 39 percent.

“While further research is needed, the ability to change or modulate the patient’s immune response has now been shown to be attainable as well as successful in treating certain stages of heart failure,” Torre said.

About the study
In the ACCLAIM trial, researchers conducted a double-blind, placebo-controlled study of a device-based IMT on 2,246 patients. All the patients had New York Heart Association (NYHA) functional class II-IV chronic heart failure, left ventricular systolic dysfunction, and hospitalization for heart failure or intravenous drug therapy in an outpatient setting within the past 12 months. Patients were randomized to receive IMT (1,213) or placebo (1,213). The study went on until all patients had been treated for at least 22 weeks. The primary endpoint was death (from any cause) or subsequent first hospitalization for cardiovascular reasons.

During a mean follow-up of 10.2 months, there were 399 primary events in the IMT group and 429 in the placebo group, giving a reduction of risk in the IMT group of 8 percent. However, in two prespecified subgroups of patients – those with no history of heart attack (919) and those with NYHA II heart failure (619), IMT was associated with a 26 percent and 39 percent reduction in the risk of primary events, respectively.

Source: Methodist Hospital, Houston

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]